TY - JOUR T1 - Serious adverse events reported from the COVID-19 vaccines: A descriptive study based on WHO database JF - medRxiv DO - 10.1101/2021.03.23.21253433 SP - 2021.03.23.21253433 AU - Siddhartha Dutta AU - Rimple Jeet Kaur AU - Jaykaran Charan AU - Pankaj Bhardwaj AU - Praveen Sharma AU - Sneha Ambwani AU - Mainul Haque AU - Ankita Tandon AU - Jha Pallavi Abhayanand AU - Sanchi Sukhija AU - S V Suman AU - Sanjeev Misra Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/24/2021.03.23.21253433.abstract N2 - Background In the light of current pandemic, the emergency approval of few COVID-19 vaccines seems to provide a ray of hope. However, their approval is solely based on limited data available from the clinical trials in a short period of time; thereby imposing a necessity to study the adverse events(AEs) associated with their use. This study therefore aims to assess the Serious Adverse Events (SAEs) associated with various COVID-19 vaccines reported in the WHO database (VigiBase®).Methods The data from VigiBase® was analyzed to assess the reported SAEs linked to various COVID-19 vaccines. The duplicates in the data were removed and were analyzed on the basis of age, gender, and seriousness of adverse events at the System Organ Classification (SOC) level and the individual Preferred Term (PT) level.Results A total 103954 adverse events reported from 32044 subjects were taken for analysis. Of 32044 subjects, majority were females (80%). Also, a total of 28799 (27.7%) SAEs were reported from the 8007 individuals. Most of the SAEs were observed in Europe (83%) amongst females (79.4%) between 18 to 64 years (80.74%) of age. Majority of SAEs (74%) were reported for BNT162b2 (Pfizer) vaccine. On system wise classification, general disorders (30%) were the commonest followed by nervous system (19.1%) and musculoskeletal (11.2%) disorders. In individual category, headache (8.1%) was the commonest, followed by pyrexia (7%) and fatigue (5.1%). The number of SAEs were reported with various vaccines were comparatively lesser as compared to the non-serious ones and incidence of death was low with all the vaccines candidates. Elderly (> 65 years) people reported more serious AEFIs as compared to other age groups.Conclusion The reported SAEs from the COVID–19 vaccines were in line with the data published in clinical trials. To link these SAEs to vaccines will need causality analysis and review of individual reports.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding received from any sourceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IEC of AIIMS Jodhpur was approached for ethical approval for this manuscript and they have given us exemption from the ethics review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data related to the study is available with the corresponding author ER -